Rivastigmine in the treatment of Alzheimer’s disease: an update

References

• AgidYDuboisBAnandR1998Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer typeCurr Ther Res5983745
   Web of Science ®Google Scholar
• AgugliaEOnorMLSainaM2004An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world settingCurr Med Res Opin2017475215537474
   PubMed Web of Science ®Google Scholar
• AlmkvistODareh-ShoriTStefanovaE2004Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer’s disease in comparison with untreated AD and MCI patientsEur J Neurol112536115061827
   PubMed Web of Science ®Google Scholar
• AnandRGharabawiGEnzA1996Efficacy and safety results of early phase studies with Exelon (ENA 713) in Alzheimer’s Disease: an overviewJ Drug Dev Clin Pract818
   Google Scholar
• AnandRMessinaJHartmanR2000Dose-response effect of rivastigmine in the treatment of Alzheimer’s diseaseInt J Geriatr Psychopharmacol26872
   Google Scholar
• AndinJEnzAGentschC2005Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expressionDement Geriatr Cogn Disord19182315383741
   PubMed Web of Science ®Google Scholar
• AupperlePMKoumarasBChenM2004Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer’s disease: results of a 52-week open label studyCurr Med Res Opin2016051215462693
   PubMed Web of Science ®Google Scholar
• BabicTBanficLPapaJ2000Spontaneous rupture of oesophagus related to rivastigmineAge Aging293701
   PubMed Web of Science ®Google Scholar
• BallardCG2002Advances in the treatment of Alzheimer’s disease: benefits of dual cholinesterase inhibitionEur Neurol47647011803198
   PubMed Web of Science ®Google Scholar
• BullockRMoulaisRSteinwachsKC2001Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer’s diseaseInt Psychogeriatric13suppl 2242S
   Google Scholar
• CleggABryantJNicholsonT2001Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic reviewHealth Technol Assess51137
   Google Scholar
• Corey-BloomJAnandRVeachJ1998A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s diseaseInt J Geriatr Psychopharmacol26872
   Google Scholar
• CummingsJLAnandRKoumarasB2000aRivastigmine provides behavioral benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26 week trialNeurology54suppl 3A4689
   Google Scholar
• CummingsJLAnandRKoumarasB2000bBehavioral benefits in Alzheimer patients residing in a nursing home following 52 weeks of rivastigmine treatmentAmerican Psychiatric Association, Annual MeetingMay 13–18Chicago21213
   Google Scholar
• CummingsJL2000Cholinesterase inhibitors: a new class of psychotropic compoundsAm J Psychiatry15741510618007
   PubMed Web of Science ®Google Scholar
• CummingsJL2003Use of cholinesterase inhibitors in clinical practice: evidence-based recommendationsAm J Geriatr Psychiatry111314512611743
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriTAlmkvistOGuanZZ2002Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 monthsNeurology595637212196650
   PubMed Web of Science ®Google Scholar
• Darreh-ShoriTHellstrom-LindahlEFlores-FloresC2004Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer’s disease patientsJ Neurochem8811021315009666
   PubMed Web of Science ®Google Scholar
• DarveshSGranthamDLHopkinsDA1998Distribution of butyrylcholinesterase in human amygdala and hippocampal formationJ Comp Neurol393374909548556
   PubMed Web of Science ®Google Scholar
• DaviesKLMaloneyAJ1976Selective loss of central cholinergic neurons in Alzheimer’s diseaseLancet2140363862
   PubMed Web of Science ®Google Scholar
• DoodyRSStevensJCBeckC2001Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of NeurologyNeurology5611546611342679
   PubMed Web of Science ®Google Scholar
• DoraiswamyPMKrishnanKRRAnandR2001Long-term effects of rivastigmine in moderately severe Alzheimer’s disease. Does early initiation of therapy offer sustained benefits?Prog Neuropsychopharmacol Biol Psychiatry267051212188103
   PubMed Web of Science ®Google Scholar
• EmreMAarslandDAlbaneseA2004Rivastigmine for dementia associated with Parkinson’s DiseaseN Engl J Med35125091815590953
   PubMed Web of Science ®Google Scholar
• ErkinjunttiTSkoogILaneR2002Rivastigmine in patients with Alzheimer’s Disease and concurrent hypertensionInt J Clin Practice567916
   PubMed Web of Science ®Google Scholar
• ErkinjunttiTSkoogILaneR2003Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brainsInt J Clin Pract577566014686563
   PubMed Web of Science ®Google Scholar
• EtemadBAnandRHartmanR2001Behavioural and cognitive benefits of rivastigmine in nursing home patients with Alzheimer’s disease and related dementias: a 26-week follow-upPoster presented at the 10th International Congress of the International Psychogeriatric Association9-–14 SseptemberNice, France
   Google Scholar
• FarlowMMessinaJAnardR2000Long-term cognitive benefits associated with the use of rivastigmine in the treatment of Alzheimer’s disease: results following two years of treatmentJ Am Geriatr Soc48108
   Web of Science ®Google Scholar
• FinkelSI2004Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer’s diseaseClin Ther269809015336465
   PubMed Web of Science ®Google Scholar
• GreigNHUtsukiTYuQ2001A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesteraseCurr Med Res Opin171596511900310
   PubMed Web of Science ®Google Scholar
• GrossbergGTStahelinHBMessinaJC2000Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medicationsInt J Geriat Psychiatry152427
   PubMed Web of Science ®Google Scholar
• GuillozetASmileyJFMashDC1997Butyrycholinesterase in the life cycle of amyloid plaquesAnn Neurol42909189403484
   PubMed Web of Science ®Google Scholar
• KennedyJSPolinskyRJJohnsonB1999Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humansInt Clin Psychopharmacol1951321
   Web of Science ®Google Scholar
• KumarVAnandRMessinaJ2000An efficacy and safety analysis of Exelon in Alzheimer’s disease patients with current vascular risk factorEur J Neurol71596910809936
   PubMed Web of Science ®Google Scholar
• Lopez-PousaSTuron-EstradaAGarre-OlmoJ2005Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer’s disease over a 6-month periodDement Geriatr Cogn Disord191899515677866
   PubMed Web of Science ®Google Scholar
• McKeithIDel SerTSpanoPF2000Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyLancet3562031611145488
   PubMed Web of Science ®Google Scholar
• MesulamMGeulaC1994Butyrylcholinesterse reactivity differentiates the amyloid plaques of aging from those of dementiaAnn Neurol3672277979218
   PubMed Web of Science ®Google Scholar
• MesulamMGuillozetAShawP2002Widely spread butyrylcholinesterase can hydrolyse acetylcholine in the normal and Alzheimer brainNeurobiol Dis9889311848688
   PubMed Web of Science ®Google Scholar
• MorettiRTorrePAntonelloRM2001Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-upEur J Neurol8361211422435
   PubMed Web of Science ®Google Scholar
• MorettiRTorrePAntonelloRM2002Rivastigmine in subcortical vascular dementia: a open 22-month studyJ Neurol Sci203141612417373
   PubMed Web of Science ®Google Scholar
• MorettiRTorrePAntonelloRM2004Rivastigmine in vascular dementiaExpert Opin Pharmacother5139941015163283
   PubMed Web of Science ®Google Scholar
• PerryEKPerryRHBlessedG1978Changes in brain cholinesterases in senile dementia of Alzheimer typeNeuropathol Appl Neurobiol42737703927
   PubMed Web of Science ®Google Scholar
• PoirierJ2002Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of actionInt J Clin Pract Suppl12761912139368
   PubMedGoogle Scholar
• PolinskyRJ1998Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s diseaseClin Ther206437
   Web of Science ®Google Scholar
• RacchiMMazzucchelliMPorrelloE2004Acetylcholinesterase inhibitors: a novel activities of old moleculesPharmachol Res5044151
   PubMed Web of Science ®Google Scholar
• ReadingPJLuceAKMcKeithIG2001Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trialMov Disord161171411748755
   PubMed Web of Science ®Google Scholar
• RomanGCRoyallDR1999Executive control function: a rational basis for diagnosis of vascular dementiaAlzheimer Dis Assoc Disord13suppl 3S69S8010609685
   PubMed Web of Science ®Google Scholar
• RomanGCErkinjuttiTWallinA2000Subcortical ischaemic vascular dementiaLancet Neurol142636 [PF 26]12849365
   PubMed Web of Science ®Google Scholar
• RomanGCSachdevPRoyallDR2004Vascular cognitive disorders: a new diagnostic category updating vascular cognitive impairment and vascular dementiaJ Neurol Sci2261–281715537526
   PubMed Web of Science ®Google Scholar
• RoslerMAnandRCicin-SainA1999Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBMJ318633810066203
   PubMed Web of Science ®Google Scholar
• RoslerMRetzWRetz-JungingerP1998Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s diseaseBehav Neurol112111611568422
   PubMed Web of Science ®Google Scholar
• SpencerCMNobleS1998Rivastigmine. A review of its use in Alzheimer’s DiseaseDrugs Aging133914119829166
   PubMed Web of Science ®Google Scholar
• TakedaALovemanECleggA2006A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of live and adverse events in Alzheimer’s diseaseInt J Geriatr Psychiatry21172816323253
   PubMed Web of Science ®Google Scholar
• TrabaceLColucciaAGaetaniS2000In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampusBrain Res8652687110821930
   PubMed Web of Science ®Google Scholar
• VenneriAMcGeownWJShanksMF2005Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer’s diseaseNeuroreport161071015671856
   PubMed Web of Science ®Google Scholar
• WeinstockM1999Selectivity of cholinesterase inhibitionCNS Drugs1230723
   Web of Science ®Google Scholar
• WildRPettitTBurnA2003Cholinesterase inhibitors for dementia with Lewy bodiesCochrane Database Syst Rev3CD00367212917981
   PubMedGoogle Scholar
• WilkinsonDGFrancisPTSchwamE2004Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: the relationship between pharmacological effects and clinical efficacyDrugs Aging214537815132713
   PubMed Web of Science ®Google Scholar
• WilkinsonDGPassmoreAPBullockR2002A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s diseaseInt J Clin Pract56441612166542
   PubMed Web of Science ®Google Scholar
• WolfsonCOremusMShuklaV2002Donepezil and rivastigmine in the treatment of Alzheimer’s disease: a best-evidence synthesis of the published data on their efficacy and cost-effectivenessClin Ther248628612117079
   PubMed Web of Science ®Google Scholar
• XieWStribleyJAChatonnettA2001Postnatal development delay and supersensitivity to organophosphate in gene targeted mice lacking acetylcholinesteraseJ Pharm Exp Therapeutics293896902
   Web of Science ®Google Scholar